Policy & Ethicsclinical trialsdrug approvalregulatory policyfda
FDA Drops Two-Trial Requirement For Drugs
9.1
WASHINGTON — The Food and Drug Administration said Wednesday it will make one pivotal study the default standard for approving new drugs and novel health products, FDA Commissioner Marty Makary and deputy Vinay Prasad wrote in a New England Journal of Medicine piece. Officials said advances in research justify the move and could spur a surge in drug development, extending single-trial approvals beyond rare or life‑threatening diseases.
Key Points
- 1Announces FDA will adopt one pivotal trial as default for new drug approvals
- 2Cites modern research precision and existing single-trial precedents for rare or serious diseases
- 3Enables faster drug development but raises questions about evidentiary standards for common conditions
Scoring Rationale
Major industry-wide regulatory shift with strong official sourcing, but unclear implementation reduces immediate clarity and predictability.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
